Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

GRANT OF SHARE OPTIONS AND RESTRICTED SHARES

This announcement is made pursuant to Rule 17.06A, 17.06B and 17.06C of the Listing Rules. The Board announces that on September 1, 2026, the Company granted 59,757 Options to 9 Grantees (the "**Option Grants**"), and 583,731 Restricted Shares to 63 Grantees (the "**RS Grants**"), in accordance with the terms of the 2024 Share Scheme, subject to acceptance by the Grantees. Among the Option Grants and RS Grants, 1,837 Options and 5,206 Restricted Shares were granted to Mr. Ede, the non-executive Director.

GRANT OF SHARE OPTIONS

The details of the Options granted to the Grantees are as follows:

Grant Date:	September 1, 2026
Number of Grantee(s):	9, of which 8 are non-connected employees (not including senior management) of the Group and Mr. Ede, the non-executive Director
Number of Options granted:	59,757
Total number of new Shares to be subscribed upon exercise of the Options granted:	57,920 to non-connected employees; and 1,837 to Mr. Ede, the non-executive Director
Consideration for the Option Grants:	HK$1.00 to be paid by each Grantee upon acceptance of the Options granted
Exercise price of the Options granted:	HK$105.76 per Share The exercise price of the Options of HK$105.76 per Share represents the highest of (i) the closing price of the Shares of HK$101.60 as stated in the daily quotation sheet issued by the Stock Exchange on the Grant Date, (ii) the average closing price of the Shares of HK$105.76 per Share as stated in the daily quotation sheets issued by the Stock Exchange for the five business days immediately preceding the Grant Date, or (iii) the nominal value of each Share, which is US$0.00001.
Exercise period of the Options:	The exercise period of the Options shall be 10 years from the Grant Date.

Vesting period:	The Options granted to the Grantees (other than Mr. Ede) shall vest in the Grantees (other than Mr. Ede) as follows: • 75% shall vest on September 1, 2029; and • 25% shall vest on September 1, 2030. The Options granted to Mr. Ede shall vest in him as follows: • 33.33% shall vest on September 1, 2027; • 33.33% shall vest on September 1, 2028; and • 33.33% shall vest on September 1, 2029.
Performance targets:	Each vesting of the Options granted to the Grantees (other than Mr. Ede) will be subject to the individual annual performance targets as stipulated in the respective grant letters entered into by the Company and each of the Grantees (other than Mr. Ede). These performance targets are set against certain benchmark of the functions in which the individual Grantee (other than Mr. Ede) serves, these functions include research and development, CMC, commercialization and supporting functions, etc. The vesting percentage of the Options at each vesting will be adjusted based on his/her annual performance appraisal. There is no performance target attached to the Options granted to Mr. Ede, the non-executive Director. Having considered that the main duties of the non-executive Director to the Company include providing strategic guidance and industry insights, and the future long-term contribution of the non-executive Director, the Remuneration Committee is of the view that in order to incentivize the non-executive Director, the grant of Options to the non-executive Director without performance targets is market competitive, consistent with the Company's remuneration policy and aligns with the purpose of the 2024 Share Scheme.
Clawback mechanism:	Where certain events specified in the rules of the 2024 Share Scheme arises, the Board may determine that, with respect to a Grantee, the Options granted but not yet exercised shall immediately lapse, and with respect to any Shares delivered or amount paid to the Grantee, the Grantee be required to transfer the same value, whether in Shares and/or cash, back to our Company (or nominee). These circumstances are: (a) the Grantee ceasing to be an eligible participant by reason of termination for cause or without notice, or as a result of being charged/penalised/convicted of an offence involving the Grantee's integrity or honesty; (b) the Grantee commits a serious misconduct or breach, including with respect to a policy or code of or other agreement with the Group, which is considered to be material; or (c) the Options granted to the Grantee will no longer be appropriate and aligned with the purpose of the 2024 Share Scheme.

GRANT OF RESTRICTED SHARES

Details of the RS Grants are as follows:

Grant Date:	September 1, 2026
Number of Grantees:	63, of which 62 are non-connected employees (not including senior management) of the Group and Mr. Ede, the non-executive Director
Number of Restricted Shares granted:	578,525 to non-connected employees; and 5,206 to Mr. Ede, the non-executive Director Each of these Restricted Shares represents the right to receive one Share on the date it vests.
Consideration for the RS Grants:	Nil
Market price of the Shares on the Grant Date and its market value:	Based on the closing price of HK$101.60 per Share as quoted on the Stock Exchange on the date of this announcement, the market value of the Restricted Shares granted to the Grantees amounts to approximately HK$59,307,069.60.
Vesting period:	The Restricted Shares granted to the Grantees (other than Mr. Ede) shall vest in the Grantees (other than Mr. Ede) as follows: • 75% shall vest on September 1, 2029; and • 25% shall vest on September 1, 2030. The Restricted Shares granted to Mr. Ede shall vest in him as follows: • 33.33% shall vest on September 1, 2027; • 33.33% shall vest on September 1, 2028; and • 33.33% shall vest on September 1, 2029.

Performance targets:	Each vesting of the Restricted Shares granted to the Grantees (other than Mr. Ede) will be subject to the individual annual performance targets as stipulated in the respective grant letters entered into by the Company and each of the Grantees (other than Mr. Ede). These performance targets are set against certain benchmark of the functions in which the individual Grantee (other than Mr. Ede) serves, these functions include research and development, CMC, commercialization and supporting functions, etc. The vesting percentage of the Restricted Shares at each vesting will be adjusted based on his/her annual performance appraisal. There is no performance target attached to the Restricted Shares granted to Mr. Ede. Having considered that the main duties of the non-executive Director to the Company include providing strategic guidance and industry insights, and the future long-term contribution of the non-executive Director, the Remuneration Committee is of the view that in order to incentivize the non-executive Director, the grant of Restricted Shares to Mr. Ede without performance targets is market competitive, consistent with the Company's remuneration policy and aligns with the purpose of the 2024 Share Scheme.
Clawback mechanism:	Where certain events specified in the rules of the 2024 Share Scheme arises, the Board may determine that, with respect to a Grantee, the Restricted Shares granted but not yet vested shall immediately lapse, and with respect to any Shares delivered or amount paid to the Grantee, the Grantee be required to transfer the same value, whether in Shares and/or cash, back to our Company (or nominee). These circumstances are: (a) the Grantee ceasing to be an eligible participant by reason of termination for cause or without notice, or as a result of being charged/penalised/convicted of an offence involving the grantee's integrity or honesty; (b) the Grantee commits a serious misconduct or breach, including with respect to a policy or code of or other agreement with the Group, which is considered to be material; or (c) the Restricted Shares granted to the Grantee will no longer be appropriate and aligned with the purpose of the 2024 Share Scheme.

Each of the grant of Options and Restricted Shares to Mr. Ede had been approved by the Board, including all the independent non-executive Directors (with Mr. Ede having abstained from voting on the resolutions relating to his grant) as well as the Remuneration Committee.

The grant of Options and Restricted Shares to Mr. Ede would not result in the Shares issued and to be issued in respect of all options and awards granted to him (excluding any options and awards lapsed in accordance with the terms of the applicable scheme) in the 12-month period up to and including the date of such grant representing in aggregate over 0.1% of the issued Shares (excluding treasury Shares). As such, the grant to Mr. Ede will not be subject to approval by the Shareholders pursuant to Rule 17.04(4) of the Listing Rules.

Save as disclosed above, none of the Grantees is a Director, chief executive or substantial shareholder of the Company or an associate of any of them. The Option Grants and the RS Grants would not result in the options and awards granted and to be granted to each individual Grantee in the 12-month period up to and including the date of such grant in aggregate to exceed 1% of the Shares in issue (excluding treasury Shares). As such, none of the Option Grants and/or RS Grants will be subject to approval by the Shareholders in accordance with Rule 17.03D(1) of the Listing Rules.

REASONS FOR AND BENEFITS OF THE OPTION GRANTS AND THE RS GRANTS

The purposes of the aforesaid Option Grants and the RS Grants are (a) to provide the Company with flexible means of remunerating, incentivizing, retaining, rewarding, compensating and/or providing benefits to eligible participants; (b) to align the interests of eligible participants with those of the Company and Shareholders by providing such eligible participants with the opportunity to acquire shareholding interests in the Company; and (c) to encourage eligible participants to contribute to the long-term growth, performance and profit of the Company and to enhance the value of the Company and its Shares for the benefit of the Company and Shareholders as a whole.

SHARES AVAILABLE FOR FUTURE GRANT UNDER THE 2024 SHARE SCHEME

The maximum number of new Shares that may be issued pursuant to all awards made under the 2024 Share Scheme is 162,838,357 Shares, with the scheme mandate limit being 10% of the total issued and outstanding Shares (excluding any treasury Shares) as at the date of the shareholders' approval of the 2024 Share Scheme. As of the date of this announcement (after taking into account the Option Grants and the RS Grants), 130,784,438 and 32,567,671 Shares are available for future grant under the aforementioned scheme mandate limit and the service provider sublimit, respectively.

DEFINITIONS

"2024 Share Scheme"	the share incentive scheme of the Company adopted by the Company on June 21, 2024
"associates"	has the same meaning ascribed to it under the Listing Rules
"Board"	the board of Directors
"China" or "PRC"	the People's Republic of China
"CMC"	chemistry, manufacturing and controls
"Company"	Innovent Biologics, Inc. 信達生物製藥, an exempted company with limited liability incorporated under the laws of the Cayman Islands on April 28, 2011, the Shares on which are listed on the main board of the Stock Exchange (stock code: 1801)
"connected person"	has the same meaning ascribed to it under the Listing Rules
"Director(s)"	the director(s) of the Company
"Grant Date"	September 1, 2026
"Grantee(s)"	the eligible participants of the Group who were granted Options and/or Restricted Shares in accordance with the 2024 Share Scheme on the Grant Date
"Group"	the Company and its subsidiaries
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Listing Rules"	Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
"Mr. Ede"	Mr. Ronald Hao Xi Ede, a non-executive Director
"Option(s)"	option(s) to subscribe for or acquire Shares which are granted under the 2024 Share Scheme
"Remuneration Committee"	the remuneration committee of the Board
"Restricted Share(s)"	restricted share(s), being a contingent right to receive Shares awarded under the 2024 Share Scheme
"Shareholder(s)"	holder(s) of Share(s) in the Company
"Share(s)"	ordinary share(s) in the issued capital of the Company with a nominal value of US$0.00001

"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary(ies)"	has the meaning ascribed to it by the Listing Rules
"substantial shareholder"	has the meaning ascribed to it by the Listing Rules
"treasury Shares"	has the meaning ascribed to it by the Listing Rules
"US$"	United States dollars, the lawful currency of the United States
"%"	per cent

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China,
September 1, 2026

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Ms. Qian Zhang as Executive Director, Mr. Ronald Hao Xi Ede as Non-executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Mr. Shuyun Chen and Dr. Stephen A. Sherwin as Independent Non-executive Directors.